Evidence map›Paper›PMID 42244601›Full record

ArticlebioRxiv : the preprint server for biology2026

Squamous-state excursions activate APOBEC3A in cancer.

Josefine Striepen, Alexandra Dananberg, Aušrinė Ruzgaitė, Alyssa Hurley, Eléonore Toufektchan, Ashley Nichols, Hannah Rosenberg, Cameron Cordero, Tony M Mertz, Roshan Xavier Norman and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Josefine StriepenMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Alexandra DananbergMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Aušrinė RuzgaitėMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Alyssa HurleyDepartment of Microbiology and Molecular Genetics, University of Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA.
Eléonore ToufektchanMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Ashley NicholsMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Hannah RosenbergMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Cameron CorderoDepartment of Microbiology and Molecular Genetics, University of Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA.
Tony M MertzDepartment of Microbiology and Molecular Genetics, University of Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA.
Roshan Xavier NormanMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Steven A RobertsDepartment of Microbiology and Molecular Genetics, University of Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA.
John MaciejowskiMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Investigating Extrachromosomal DNA (ecDNA) Segregation and Repair in CancerR01CA304441 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MACIEJOWSKI, JOHN, SFEIR, AGNEL · 2025 to 2025
$3.2M
Immune control and genomic instability at micronucleiR37CA261183 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOHN MACIEJOWSKI · 2022 to 2026
$2.4M
Regulation of APOBEC3 cytidine deaminase-induced mutation during cancerdevelopmentR01CA269784 · NCI · WASHINGTON STATE UNIVERSITY · PI STEVEN A ROBERTS · 2023 to 2026
$2.0M
Molecular origins and impact of APOBEC3 mutagenesis in cancerR01CA270102 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MACIEJOWSKI, JOHN · 2022 to 2025
$1.9M
Genomic Instability in Lung Cancer: Unraveling the Impact of the APOBEC3 FamilyF31CA290850 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Josefine Striepen · 2025 to 2026
$100k
NCI NIH HHS F31 CA290850NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA269784NCI NIH HHS R01 CA270102NCI NIH HHS R01 CA304441NCI NIH HHS R37 CA261183
6 · The paper itself

Abstract

The cytidine deaminase APOBEC3A is a major endogenous mutagen in human cancer, yet is rarely captured in bulk tumor RNA or protein profiles despite the prominent mutational scars it leaves in cancer genomes. The origin of these episodic mutational bursts has remained unclear, with prevailing models emphasizing sustained inflammatory signaling. Here, we show that APOBEC3A is induced in a rare subpopulation of cancer cells engaging a transient squamous differentiation program, linking APOBEC3A mutagenesis to lineage-state plasticity rather than persistent inflammatory signaling. Across breast and lung cancer cell lines and patient tumors, keratinocyte differentiation markers, including the stress keratins KRT6A and KRT16, are the strongest correlates of endogenous APOBEC3A expression. These days-long squamous-state excursions explain how APOBEC3A can leave durable mutational scars while remaining largely invisible to bulk tumor RNA and protein profiling. APOBEC3A catalytic activity reinforces selected components of this program through uracil excision and JNK-AP-1 signaling. The squamous differentiation transcription factor ZNF750 promotes APOBEC3A induction during squamous-state engagement in breast and lung cancer models. In established human squamous tumors, however, ZNF750 loss-of-function is associated with elevated APOBEC3A expression and APOBEC mutagenesis, revealing lineage-context-dependent regulation. These findings identify a transient differentiation state as a mutagenic intermediate, coupling cell-state plasticity to cancer genome evolution.

Indexed as

APOBEC3Aepisodic gene expressionkeratinocyte differentiationlineage plasticitymutational signaturestranscriptional reprogrammingZNF750

Identifiers

PMID42244601
PMCPMC13232299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.